Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Recombinant virus encoding one or more heterologous proteins...
Reexamination Certificate
2004-11-04
2009-11-24
Chen, Stacy B (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Recombinant virus encoding one or more heterologous proteins...
C424S211100
Reexamination Certificate
active
07622123
ABSTRACT:
Chimeric human-bovine parainfluenza viruses (PIVs) are infectious and attenuated in humans and other mammals and useful individually or in combination in vaccine formulations for eliciting an anti-PIV immune response. Also provided are isolated polynucleotide molecules and vectors incorporating a chimeric PIV genome or antigenome which includes a partial or complete human or bovine PIV “background” genome or antigenome combined or integrated with one or more heterologous gene(s) or genome segment(s) of a different PIV. Chimeric human-bovine PIV of the invention include a partial or complete “background” PIV genome or antigenome derived from or patterned after a human or bovine PIV virus combined with one or more heterologous gene(s) or genome segment(s) of a different PIV virus to form the human-bovine chimeric PIV genome or antigenome.
REFERENCES:
patent: 4683195 (1987-07-01), Mullis
patent: 4683202 (1987-07-01), Mullis
patent: 5716821 (1998-02-01), Wertz et al.
patent: 5789229 (1998-08-01), Wertz et al.
patent: 5869036 (1999-02-01), Belshe et al.
patent: 6033886 (2000-03-01), Conzelmann
patent: 6136585 (2000-10-01), Ball et al.
patent: 6264957 (2001-07-01), Collins
patent: 0 440 219 (1991-08-01), None
patent: 0 702 085 (1996-03-01), None
patent: WO 92/01471 (1992-02-01), None
patent: WO 93/14207 (1993-07-01), None
patent: WO 93/21310 (1993-10-01), None
patent: WO 97/06270 (1997-02-01), None
patent: WO 97/11093 (1997-03-01), None
patent: WO 97/12032 (1997-04-01), None
patent: WO 97/20468 (1997-06-01), None
patent: WO 98/02530 (1998-01-01), None
patent: WO 98/43668 (1998-10-01), None
patent: WO 98/53078 (1998-11-01), None
patent: WO 99/02657 (1999-01-01), None
patent: WO 99/15631 (1999-04-01), None
patent: WO 99/24564 (1999-05-01), None
patent: WO 00/61611 (2000-10-01), None
patent: WO 00/61737 (2000-10-01), None
patent: WO 01/04271 (2001-01-01), None
patent: WO 01/04321 (2001-01-01), None
patent: WO 01/04335 (2001-01-01), None
Bailly et al., “A Recombinant Human Parainfluenza Virus Type 3 (PIV3) In Which the Nucleocapsid N Protein Has Been Replaced”, Journal Virology, vol. 74, No. 7, 3188-3195 (2000).
Baron et al., “Rescue of Rinderpest Virus From Cloned Cdna”, Journal Virology, vol. 71, No. 2, 1265-1271 (1997).
Bellini et al., “Measles Virus P Gene Codes for Two Proteins”, Journal Virology, vol. 53, No. 3, 908-919 (1985).
Belshe et al., “Cold Adaptation of Parainfluenza Virus Type 3”, Journal Medical Virology, vol. 10(4), 235-242 (1982).
Belshe et al., “Comparison of Enzyme-Linked Immunosorbent Assay and Neutralization Techniques for Measurement of Antibody”, Infect And Immun. vol. 37, 160-165 (1982).
Blumberg et al., “Measles Virus L Protein Evidences Elements of Ancestral RNA Polymerase,” Virology, 164:487-497, 1988.
Buchholz et al., “Chimeric Bovine Respiratory Syncytial Virus With Glycoprotein Gene Substitutions,” Journal Virology, vol. 74, No. 3, 1187-1199 (2000).
Buchholz et al., “Generation of Bovine Respiratory Syncytial Virus (BRSV) from cDNA,” Journal Virology, vol. 73, No. 1, 251-259 (1999).
Bukreyev et al., “Recombinant Respiratory Syncytial virus from which the Entire SH Gene has been Deleted Grows Efficiently in Cell Culture and Exhibits Site-Specific Attenuation in the Respiratory Tract of the Mouse,” J. Virol. 71:8973-8982, 1977.
Bukreyev et al., “Interferon Gamma Expressed By A Recombinant Respiratory Syncytial Virus Attenuates Virus Replication In Mice,” Proc. Natl. Acad. Sci. USA, vol. 96, 2367-2372 (1999).
Bukreyev et al., “Recovery of Infectious Respiratory Syncytial Virus Expressing An Additional, Foreign Gene,” Journal Virology, vol. 70, No. 10, 6634-6641 (1996).
Cadd et al., “The Sendai Paramyxiovirus Accessory C Proteins Inhibit Viral Genome Amplification in Promoter-Specific Fashion,” J. Virol 70: 5067-74, 1996.
Cahour et al., “Growth-Restricted Dengue Virus Mutants Containing Deletions in the 5 Noncoding Region of the RNA Genome,” Virology, vol. 207, 68-76 (1995).
Cattaneo et al., “Measles Virus Editing Provides Additional Cytosine-Rich Protein,” Cell, vol. 56, 759-764, (1989).
Cheng et al., “Effective Amplification of Long Targets From Cloned Inserts,” Proc. Natl. Acad. Sci. USA, vol. 91, 5695-5699 (1994).
Clarke et al., “Rescue of Mumps Virus From cDNA,” J Virology, vol. 74, No. 10, 4831-4838 (2000).
Clements et al., “Comparison of Virologic—Immunologic Resp. of Volunteers To Live Avian-Human Influenza A H3N2 Reassortant,” Journal Clinical Microbiology, vol. 27, No. 1, 219-222 (1989).
Clements et al., “Evaluation of Bovine Cold-Adapted Human, and Wild Type Human Parainfluenza Type 3 Viruses in Adult Volunteers,” J. Clinical Microbiology, vol. 29, 1175-1182 (1991).
Clements et al., “Use of Single-Gene Reassortant Viruses to Study Role of Anain Influenza A Virus,” Journal Clinical Microbiology, vol. 30, No. 3, 655-662 (1992).
Clements-Mann et al., “Safety and Immunogenicity of Live Attenuated Human-Bovine (UK) Reassortant Rotavirus Vaccines VP7 Specificity,” Vaccine vol. 17, 2715-2725 (1999).
Collins et al., “Parainfluenza Viruses,” Fields Virology 3rd ed., Lippincott-Raven Publishers, Philadelphia 1205-1241, (1996).
Collins et al., “Rescue of a 7502-Nucleotide (49.3% of Full-Length) Synthetic Analog of Respiratory Syncytial Virus Genomic RNA,” Virology 195:252-256, 1993.
Collins et al., “Rescue of Synthetic Analogs of Respiratory Syncytial Virus Genomic RNA and Effect of Truncations and Mutations on the Expression of a Foreign Reporter Gene,” Proc. Natl. Acad. Sci. USA, 88:9663-9667, 1991.
Collins et al., “Production of Infectious Human Respiratory Syncytial Virus From Cloned cDNA,” Pro. Natl. Acad. Sci., vol. 92, 11563-11567 (1995).
Connors et al., “A Cold-Passaged Attenuated Strain of Human Respiratory Syncytial Virus Contains Mutations in the F and L Genes,” Virology 208:478-484, 1995.
Conzelmann et al., “Rescue of Synthetic Genomic RNA Analogs of Rabies Virus by Plasmid-Encoded Proteins,” J. Virol. 68: 713-719, 1994.
Conzelmann et al., “Genetic Manipulation of Non-Segmented Negative-Strand RNA Viruses,” Journal General Virology, vol. 77, 381-389 (1996).
Cook et al., “Antigenic Relationships Among the “Newer” Myxoviruses (Parainfluenza),” Amer. Jour. Hyq. 69:250, 1959.
Cook et al., “In Vivo Antigenic Studies of Parainfluenza Viruses,” American Journal of Hygiene, vol. 77, 150-159 (1962).
Corsoro and Pearson, “Enhancing the Efficiency of DNA Mediated Gene Transfer In Mammalian Cells,” Somatic Cell Genetics, vol. 7, No. 5, 603-616 (1981).
Crookshanks et al., “Evaluation of Cold-Adapted And Temperature-Sensitive Mutants Of Parainfluenza Virus Type 3,” Journal Medical Virology, vol. 13, 243-249 (1984).
Crowe et al., “A Further Attenuated Derivative of a Cold-Passaged Temperature-Sensitive Mutant of Human Respiratory Syncytial Virus Retains Immunogenicity and Protective Efficacy Against Wild-Type Challenge in Seronegative Chimpanzees,” Vaccine 12:783-790, 1994.
Crowe et al., “Acquisition of thetsPhenotype by a Chemically Mutagenized Cold-Passaged Human Respiratory Syncytial Virus Vaccine Candidate Results from the Acquisition of a Single Mutation in the Polymerase (L) Gene,” Virus Genes 13: 269-273, 1996.
Crowe et al., “Cold-Passaged, Temperature-Sensitive Mutants of Human Respiratory Syncytial Virus (RSV),” Vaccine, vol. 13, No. 9, 847-855 (1995).
Curran et al., “The Sendai Virus Nonstructural C Proteins Specifically Inhibit Viral mRNA Synthesis,” Virology 189: 647-656, 1992.
Curran et al., “Sendai Virus P Gene Produces Multiple Proteins From Overlapping Open Reading Frames, Enzyme,” vol. 44, 244-249 (199
Collins Peter L.
Murphy Brian R.
Schmidt Alexander C.
Skiadopoulos Mario H.
Chen Stacy B
The United States of America as represented by the Department of
Woodcock & Washburn LLP
LandOfFree
Attenuated human-bovine chimeric parainfluenza virus (PIV)... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Attenuated human-bovine chimeric parainfluenza virus (PIV)..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Attenuated human-bovine chimeric parainfluenza virus (PIV)... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4072118